Yup just remember my price valuation advice last year was to project the share price value was “ uncapped” based on “ if you owned the patent on penicillin 40 years or 80 years ago what would that be worth now” if all penicillin derivatives are now increasingly failing due to anti microbial resistance , whats that solution replacement going to be worth in the near to longer term future? if recce derivative products also show strong efficacy against covid virus ( similAr to proven efficacy already against sars, influenza A etc) how does that add additional unexpected value ? now alternative high response applications are emerging right on the cusp of commercialisation burns and open wounds topical treatments gonorrhoea urinary tract infection sepsis entering stage one trials very very soon 5 major fronts - success on any one of those to commercialisation will drive this co capitalisation prospects so far north from here its hard to assess
im not going to try and quantify it , but you can clearly see the numbers have billions not millions in the calculations
RCE Price at posting:
$1.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)